Navigation Links
NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
Date:5/13/2008

SOPHIA ANTIPOLIS, France, May 13 /PRNewswire-FirstCall/ -- NicOx S.A. (Eurolist: COX) today announced that Merck & Co., Inc. has initiated the first in a series of planned clinical studies, in mild to moderate hypertensive patients, under the companies' collaborative agreement to develop new nitric oxide-donating antihypertensive agents using NicOx' proprietary technology. Three drug candidates have now been selected from the companies' joint research program, of which two have completed initial dose ranging studies in healthy volunteers under the exploratory clinical study paradigm with encouraging results.

Merck plans to conduct a number of clinical studies in hypertensive patients involving single and multiple ascending dosing, prior to the selection of a compound to be advanced into phase 2. The most advanced candidate is now being evaluated in the first of these studies, which is a single ascending dose trial in mild to moderate hypertensive patients. The main objectives of this study are to assess the efficacy, safety, tolerability and pharmacokinetics of single ascending doses of this candidate. Subsequent studies will assess multiple ascending doses.

"The initiation of this series of clinical studies in hypertensive patients is a very important step towards delivering a new treatment paradigm for hypertension, where the medical need remains significant," commented Jacques Djian M.D., NicOx' Cardiometabolic Area Leader. "We believe these drug candidates have considerable potential as improved antihypertensive agents based on their nitric oxide-donating properties and we hope they will deliver a major advance in antihypertensive treatment for patients worldwide."

In July 2007, NicOx announced the initiation of the first in a series of studies in healthy volunteers for the selected candidates (see press release of July 16, 2007). Merck is responsible for funding and performing the development of these compounds going forward.


'/>"/>

SOURCE NicOx S.A.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
2. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
3. NicOx Naproxcinod ABPM Data Presented at American Heart Association
4. NicOx Naproxcinod Phase 3 Results Presented at American College of Rheumatology
5. NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
6. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
7. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
8. Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... Wis. , July 14, 2014 Lumin ... purchased the assets of PatientTrak, the leading provider of ... headquarters from Illinois to ... name is Lumin which means light and our mission ... improve patient satisfaction, increase efficiencies and reduce costs," said ...
(Date:7/14/2014)... 14, 2014  More than any other generation, Millennials born ... computers -- but their eyes don,t. These mobile devices demand ... and the eye has not evolved to cope with them. ... can do comfortably often results in tired eyes, focusing problems, ... Eye Strain. Now ZEISS has invented a new type of ...
(Date:7/14/2014)...  Today, ATS Labs, Inc. (ATS), majority owned by ... of MicroTest Labs, Inc. (MTL) of Agawam ... first step in the strategy of ATS to expand ... the medical device and biopharmaceutical industries.  The combined companies ... , a name that personifies the quality and accuracy ...
Breaking Medicine Technology:Lumin Medical Purchases PatientTrak 2Lumin Medical Purchases PatientTrak 3New Eyeglass Lens Helps Our Eyes Keep Up with our Digital Lives 2New Eyeglass Lens Helps Our Eyes Keep Up with our Digital Lives 3ATS Labs, Inc. Announces the Acquisition of MicroTest Labs, Inc. 2ATS Labs, Inc. Announces the Acquisition of MicroTest Labs, Inc. 3
... 28, 2012   OncoSec Medical Incorporated (OTCBB: ONCS), ... ElectroOncology therapies to treat solid tumor cancers, today announced ... by the University of California San Francisco and the ... clinical trial evaluating OncoSec,s OMS ElectroImmunotherapy for ...
... from visual impairment due to autism, brain injury, stroke or ... a revolutionary new therapy program using specially designed games and ... Therapy Program uses a web-based application in which patients ... system dysfunction and strengthen visual skills. The application was created ...
Cached Medicine Technology:OncoSec Doses First Patient in Phase II Clinical Trial for Metastatic Melanoma 2OncoSec Doses First Patient in Phase II Clinical Trial for Metastatic Melanoma 3OncoSec Doses First Patient in Phase II Clinical Trial for Metastatic Melanoma 4New Therapy Program Allows Doctors to Prescribe Computer Games on iPad to Treat Visual Impairment 2
(Date:7/14/2014)... pathologist Lukas Kenner and his colleagues have developed a ... tissue sections and demonstrate the presence of specific biomarkers ... of the disease and leads to the most suitable ... study, "Two independent pathologists concur with each other only ... developed software offers, for the first time, the option ...
(Date:7/14/2014)... July 14, 2014 Last month Bromell ... their website. The webpage features more detailed information on ... including motorcycles, RVs, ATVs, and boats in the state ... this new feature to the website in order to ... helps encompass the purpose of the website, which is ...
(Date:7/14/2014)... is he who "begins to age". But laboratory biology ... not a synonym of ageing, it is also not ... a badly named physiological process that those who do ... That is the case of Manuel Serrano, from the ... world,s leading experts on senescence, who has just published ...
(Date:7/14/2014)... may buffer some of the adverse health effects of ... researchers from the American Cancer Society, The Cooper Institute, ... the journal Mayo Clinic Proceeding s, and finds ... blood markers associated with cardiovascular disease is markedly less ... has been linked to an increase risk of obesity, ...
(Date:7/14/2014)... Botanica Day Spa announced last month that their ... the day spa in down town Clearwater, FL on ... refreshments will be served as clients are invited to ... and great deals on spa services, including the ... (also known as “facial shaving”) is a simple and ...
Breaking Medicine News(10 mins):Health News:Scientists developed new technology for the diagnosis of cancer cells 2Health News:Manuel Serrano proposes a new vision of a process wrongly associated with ageing 2Health News:Manuel Serrano proposes a new vision of a process wrongly associated with ageing 3Health News:Physical fitness associated with less pronounced effect of sedentary behavior 2Health News:Botanica Day Spa to Feature Dermaplaning at Upcoming Open House 2Health News:Botanica Day Spa to Feature Dermaplaning at Upcoming Open House 3
... mortality for hospitalized patients, study found , , TUESDAY, Oct. ... hospitalized for pneumonia was one-third lower for those taking ... a Danish study found. , While the findings are ... doctors can prescribe statins as infection fighters, experts said. ...
... Intentional Interference with ... Prospective Business Advantage, CAMBRIDGE, Mass., Oct. ... it had filed an action for injunctive,relief and damages against ... Hemopure, hemoglobin glutamer-250,(bovine), Biopure,s oxygen therapeutic product for human use. ...
... ... Cost Reduction Efforts Continue to Generate Results ... Step for Visian Toric ICL Application to ... FDA, MONROVIA, Calif., Oct. 28 STAAR ...
... disease rises as the joint ailment worsens, research shows ... (RA) may increase the risk of gum disease, a ... link between RA and periodontal disease, a condition where ... from the gums, loss of bony support, and possible ...
... 28 Blue Mountain Quality,Resources, Inc. announced ... Regulatory Asset Manager(R) to satisfy their immediate ... their enterprise-wide,SAP(R) implementation., "Alexion is committed ... in,its manufacturing facilities and other operations," explains ...
... 28 NASA satellite data can,improve forecasts of ... that can,benefit public health managers. Scientists announced the ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081007/38461LOGO ), Led by ... Mexico in,Albuquerque, and William Sprigg of the University ...
Cached Medicine News:Health News:Statins Reduced Death Risk From Pneumonia 2Health News:Statins Reduced Death Risk From Pneumonia 3Health News:Biopure Sues National Institutes of Health Official 2Health News:Biopure Sues National Institutes of Health Official 3Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 2Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 3Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 4Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 5Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 6Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 7Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 8Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 9Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 10Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 11Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 12Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 13Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 14Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 15Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 16Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 17Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 18Health News:Rheumatoid Arthritis May Harm Gums 2Health News:Alexion Pharmaceuticals Chooses Blue Mountain Regulatory Asset Manager(R) for Best-in-class Calibration Management Integrated with SAP(R) 2Health News:NASA-Enhanced Dust Storm Predictions to Aid Health Community 2Health News:NASA-Enhanced Dust Storm Predictions to Aid Health Community 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: